Literature DB >> 15579494

Free exchange across cells, and echistatin-sensitive membrane target for the metastasis inhibitor NAMI-A (imidazolium trans-imidazole dimethyl sulfoxide tetrachlororuthenate) on KB tumor cells.

F Frausin1, V Scarcia, M Cocchietto, A Furlani, B Serli, E Alessio, G Sava.   

Abstract

The duration of cell proadhesive effects induced by imidazolium trans-imidazole dimethyl sulfoxide tetrachlororuthenate (NAMI-A), a compound endowed with in vivo antimetastatic properties, was tested in vitro on the human epithelial tumor cell line KB. The intensity of proadhesive effects continues to increase up to 48 to 72 h after NAMI-A withdrawal and declines only after 96 h. The proadhesive effect on cells seeded on fibronectin is greater than on plastic, since it already reaches its maximum after 24 h. This effect suggests a role for integrin activation, which is further stressed by the inhibitory activity of the disintegrin molecule echistatin. The intensity and duration of NAMI-A's proadhesive effects are correlated to cell exposure time and to the rapid release of NAMI-A metabolites in the culture medium in the first 5 min after drug withdrawal. These metabolites are probably neutral species with ruthenium-bound bioligands to allow for the rapid exchange between cells and extracellular medium. These data suggest a long-lasting effect of NAMI-A in biological systems, even at very low concentrations, and stress the low and reversible effects on kidney, where it naturally concentrates. These data on proadhesive effects are, further, relevant for in vivo antimetastatic effects, as this adhesion is associated to cell motility and invasion, which in turn are related to tumor malignancy and metastasis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15579494     DOI: 10.1124/jpet.104.078352

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.

Authors:  Suzanne Leijen; Sjaak A Burgers; Paul Baas; Dick Pluim; Matthijs Tibben; Erik van Werkhoven; Enzo Alessio; Gianni Sava; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2014-10-25       Impact factor: 3.850

2.  Theoretical and experimental studies of phenol oxidation by ruthenium complex with N,N,N-tris(benzimidazol-2yl-methyl)amine.

Authors:  J Guadalupe Hernandez; Antonio Romero Silva; Pandiyan Thangarasu; Rafael Herrera Najera; Alfonso Duran Moreno; M Teresa Orta Ledesma; Julian Cruz-Borbolla; Narinder Singh
Journal:  J Mol Model       Date:  2015-08-08       Impact factor: 1.810

3.  Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.

Authors:  L Brescacin; A Masi; G Sava; A Bergamo
Journal:  J Biol Inorg Chem       Date:  2015-09-14       Impact factor: 3.358

4.  Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c.

Authors:  Angela Casini; Guido Mastrobuoni; Mattia Terenghi; Chiara Gabbiani; Enrico Monzani; Gloriano Moneti; Luigi Casella; Luigi Messori
Journal:  J Biol Inorg Chem       Date:  2007-08-07       Impact factor: 3.358

5.  Experimental and DFT studies of sulfadiazine 'piano-stool' Ru(ii) and Rh(iii) complexes.

Authors:  Ahmed M Mansour; Krzysztof Radacki
Journal:  RSC Adv       Date:  2020-03-12       Impact factor: 4.036

6.  The Significant Influence of a Second Metal on the Antiproliferative Properties of the Complex [Ru(η6 -C10 H14 )(Cl2 )(dmoPTA)].

Authors:  Nazanin Kordestani; Elisa Abas; Laura Grasa; Andres Alguacil; Franco Scalambra; Antonio Romerosa
Journal:  Chemistry       Date:  2021-12-08       Impact factor: 5.020

Review 7.  Fighting Cancer with Transition Metal Complexes: From Naked DNA to Protein and Chromatin Targeting Strategies.

Authors:  Giulia Palermo; Alessandra Magistrato; Tina Riedel; Thibaud von Erlach; Curt A Davey; Paul J Dyson; Ursula Rothlisberger
Journal:  ChemMedChem       Date:  2015-12-04       Impact factor: 3.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.